Clvs Stock Forecast Zacks. Earnings and regulatory updates from regeneron (regn) and vertex (vrtx) are a few key highlights from the biotech sector during the past week. Boulder — pharmaceutical company clovis oncology inc.
Clvs) saw its revenues shrink by 10% year over year in the first quarter of 2021, resulting in a sell off of company stock in early trading wednesday. Boulder — pharmaceutical company clovis oncology inc. The lowest sales estimate is $37.02 million and the highest is $37.04 mill
Table of Contents
Zacks Zacks Is The Leading Investment Research Firm Focusing On Stock Research, Analysis And Recommendations.
Two analysts have made estimates for clovis oncology's earnings. The lowest sales estimate is $37.02 million and the highest is $37.04 mill In 1978, our founder discovered the power of earnings estimate revisions to enable.
View The Latest News, Buy/Sell Ratings, Sec Filings And Insider Transactions For Your Stocks.
Today, you will also get zacks' 7 best stocks for the next 30 days. Boulder — pharmaceutical company clovis oncology inc. Do the numbers hold clues to what lies ahead for the stock?
Clvs) Saw Its Revenues Shrink By 10% Year Over Year In The First Quarter Of 2021, Resulting In A Sell Off Of Company Stock In Early Trading Wednesday.
Earnings and regulatory updates from regeneron (regn) and vertex (vrtx) are a few key highlights from the biotech sector during the past week. Regeneron (regn) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended march 2022. The company posted revenues of $34.2 million in the most recent quarter and a net loss of $60.2 million, or 44 cents per share, which missed zacks.
